nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2B6—Sorafenib—thyroid cancer	0.0828	0.223	CbGbCtD
Paroxetine—CYP2C8—Sorafenib—thyroid cancer	0.0627	0.169	CbGbCtD
Paroxetine—CYP2B6—Doxorubicin—thyroid cancer	0.0502	0.135	CbGbCtD
Paroxetine—CYP2C9—Sorafenib—thyroid cancer	0.0437	0.118	CbGbCtD
Paroxetine—ABCB1—Sorafenib—thyroid cancer	0.0424	0.114	CbGbCtD
Paroxetine—CYP2D6—Sorafenib—thyroid cancer	0.04	0.108	CbGbCtD
Paroxetine—ABCB1—Doxorubicin—thyroid cancer	0.0258	0.0692	CbGbCtD
Paroxetine—CYP2D6—Doxorubicin—thyroid cancer	0.0243	0.0652	CbGbCtD
Paroxetine—TACR1—trachea—thyroid cancer	0.000424	0.11	CbGeAlD
Paroxetine—TACR1—head—thyroid cancer	0.000298	0.0774	CbGeAlD
Paroxetine—Dizziness—Sorafenib—thyroid cancer	0.000289	0.000528	CcSEcCtD
Paroxetine—Mood swings—Doxorubicin—thyroid cancer	0.000288	0.000526	CcSEcCtD
Paroxetine—Ataxia—Doxorubicin—thyroid cancer	0.000285	0.000522	CcSEcCtD
Paroxetine—Asthma—Epirubicin—thyroid cancer	0.000284	0.000518	CcSEcCtD
Paroxetine—Influenza—Epirubicin—thyroid cancer	0.000284	0.000518	CcSEcCtD
Paroxetine—Dysphagia—Epirubicin—thyroid cancer	0.000284	0.000518	CcSEcCtD
Paroxetine—Dehydration—Doxorubicin—thyroid cancer	0.000282	0.000516	CcSEcCtD
Paroxetine—Eosinophilia—Epirubicin—thyroid cancer	0.000281	0.000513	CcSEcCtD
Paroxetine—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00028	0.000512	CcSEcCtD
Paroxetine—CHRM4—head—thyroid cancer	0.00028	0.0728	CbGeAlD
Paroxetine—Dry skin—Doxorubicin—thyroid cancer	0.000278	0.000509	CcSEcCtD
Paroxetine—Pancreatitis—Epirubicin—thyroid cancer	0.000278	0.000508	CcSEcCtD
Paroxetine—Vomiting—Sorafenib—thyroid cancer	0.000277	0.000507	CcSEcCtD
Paroxetine—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000277	0.000507	CcSEcCtD
Paroxetine—Hypokalaemia—Doxorubicin—thyroid cancer	0.000276	0.000505	CcSEcCtD
Paroxetine—Angina pectoris—Epirubicin—thyroid cancer	0.000276	0.000505	CcSEcCtD
Paroxetine—Rash—Sorafenib—thyroid cancer	0.000275	0.000503	CcSEcCtD
Paroxetine—Dermatitis—Sorafenib—thyroid cancer	0.000275	0.000502	CcSEcCtD
Paroxetine—Breast disorder—Doxorubicin—thyroid cancer	0.000274	0.000502	CcSEcCtD
Paroxetine—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000273	0.0005	CcSEcCtD
Paroxetine—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000273	0.0005	CcSEcCtD
Paroxetine—Headache—Sorafenib—thyroid cancer	0.000273	0.0005	CcSEcCtD
Paroxetine—Bronchitis—Epirubicin—thyroid cancer	0.000273	0.000499	CcSEcCtD
Paroxetine—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000271	0.000496	CcSEcCtD
Paroxetine—Pancytopenia—Epirubicin—thyroid cancer	0.000269	0.000492	CcSEcCtD
Paroxetine—Gastritis—Doxorubicin—thyroid cancer	0.000269	0.000491	CcSEcCtD
Paroxetine—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000268	0.000489	CcSEcCtD
Paroxetine—Muscular weakness—Doxorubicin—thyroid cancer	0.000268	0.000489	CcSEcCtD
Paroxetine—Dysuria—Epirubicin—thyroid cancer	0.000265	0.000485	CcSEcCtD
Paroxetine—Influenza—Doxorubicin—thyroid cancer	0.000262	0.00048	CcSEcCtD
Paroxetine—Asthma—Doxorubicin—thyroid cancer	0.000262	0.00048	CcSEcCtD
Paroxetine—Dysphagia—Doxorubicin—thyroid cancer	0.000262	0.00048	CcSEcCtD
Paroxetine—Pollakiuria—Epirubicin—thyroid cancer	0.000262	0.000479	CcSEcCtD
Paroxetine—Eosinophilia—Doxorubicin—thyroid cancer	0.00026	0.000475	CcSEcCtD
Paroxetine—Nausea—Sorafenib—thyroid cancer	0.000259	0.000474	CcSEcCtD
Paroxetine—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000259	0.000473	CcSEcCtD
Paroxetine—Weight increased—Epirubicin—thyroid cancer	0.000258	0.000472	CcSEcCtD
Paroxetine—Pancreatitis—Doxorubicin—thyroid cancer	0.000257	0.00047	CcSEcCtD
Paroxetine—Weight decreased—Epirubicin—thyroid cancer	0.000257	0.000469	CcSEcCtD
Paroxetine—Hyperglycaemia—Epirubicin—thyroid cancer	0.000256	0.000468	CcSEcCtD
Paroxetine—Angina pectoris—Doxorubicin—thyroid cancer	0.000256	0.000467	CcSEcCtD
Paroxetine—Pneumonia—Epirubicin—thyroid cancer	0.000254	0.000465	CcSEcCtD
Paroxetine—Drowsiness—Epirubicin—thyroid cancer	0.000253	0.000462	CcSEcCtD
Paroxetine—CHRM1—saliva-secreting gland—thyroid cancer	0.000252	0.0656	CbGeAlD
Paroxetine—Bronchitis—Doxorubicin—thyroid cancer	0.000252	0.000461	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000251	0.000458	CcSEcCtD
Paroxetine—Pancytopenia—Doxorubicin—thyroid cancer	0.000249	0.000456	CcSEcCtD
Paroxetine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000248	0.000453	CcSEcCtD
Paroxetine—Jaundice—Epirubicin—thyroid cancer	0.000246	0.000451	CcSEcCtD
Paroxetine—Stomatitis—Epirubicin—thyroid cancer	0.000246	0.000451	CcSEcCtD
Paroxetine—Conjunctivitis—Epirubicin—thyroid cancer	0.000246	0.000449	CcSEcCtD
Paroxetine—Urinary tract infection—Epirubicin—thyroid cancer	0.000246	0.000449	CcSEcCtD
Paroxetine—Dysuria—Doxorubicin—thyroid cancer	0.000245	0.000449	CcSEcCtD
Paroxetine—Sweating—Epirubicin—thyroid cancer	0.000242	0.000443	CcSEcCtD
Paroxetine—Pollakiuria—Doxorubicin—thyroid cancer	0.000242	0.000443	CcSEcCtD
Paroxetine—Haematuria—Epirubicin—thyroid cancer	0.000241	0.000441	CcSEcCtD
Paroxetine—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000239	0.000438	CcSEcCtD
Paroxetine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000239	0.000437	CcSEcCtD
Paroxetine—Weight increased—Doxorubicin—thyroid cancer	0.000239	0.000437	CcSEcCtD
Paroxetine—Epistaxis—Epirubicin—thyroid cancer	0.000238	0.000436	CcSEcCtD
Paroxetine—Weight decreased—Doxorubicin—thyroid cancer	0.000237	0.000434	CcSEcCtD
Paroxetine—Sinusitis—Epirubicin—thyroid cancer	0.000237	0.000434	CcSEcCtD
Paroxetine—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000237	0.000433	CcSEcCtD
Paroxetine—Agranulocytosis—Epirubicin—thyroid cancer	0.000236	0.000431	CcSEcCtD
Paroxetine—Pneumonia—Doxorubicin—thyroid cancer	0.000235	0.00043	CcSEcCtD
Paroxetine—Drowsiness—Doxorubicin—thyroid cancer	0.000234	0.000428	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000232	0.000424	CcSEcCtD
Paroxetine—Bradycardia—Epirubicin—thyroid cancer	0.000231	0.000422	CcSEcCtD
Paroxetine—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000229	0.000419	CcSEcCtD
Paroxetine—Haemoglobin—Epirubicin—thyroid cancer	0.000228	0.000417	CcSEcCtD
Paroxetine—Jaundice—Doxorubicin—thyroid cancer	0.000228	0.000417	CcSEcCtD
Paroxetine—Stomatitis—Doxorubicin—thyroid cancer	0.000228	0.000417	CcSEcCtD
Paroxetine—Rhinitis—Epirubicin—thyroid cancer	0.000228	0.000416	CcSEcCtD
Paroxetine—Conjunctivitis—Doxorubicin—thyroid cancer	0.000227	0.000416	CcSEcCtD
Paroxetine—Urinary tract infection—Doxorubicin—thyroid cancer	0.000227	0.000416	CcSEcCtD
Paroxetine—Haemorrhage—Epirubicin—thyroid cancer	0.000227	0.000415	CcSEcCtD
Paroxetine—Hepatitis—Epirubicin—thyroid cancer	0.000227	0.000415	CcSEcCtD
Paroxetine—Hypoaesthesia—Epirubicin—thyroid cancer	0.000226	0.000413	CcSEcCtD
Paroxetine—CHRM3—saliva-secreting gland—thyroid cancer	0.000226	0.0587	CbGeAlD
Paroxetine—Pharyngitis—Epirubicin—thyroid cancer	0.000225	0.000412	CcSEcCtD
Paroxetine—Sweating—Doxorubicin—thyroid cancer	0.000224	0.00041	CcSEcCtD
Paroxetine—Oedema peripheral—Epirubicin—thyroid cancer	0.000224	0.000409	CcSEcCtD
Paroxetine—Haematuria—Doxorubicin—thyroid cancer	0.000223	0.000408	CcSEcCtD
Paroxetine—Connective tissue disorder—Epirubicin—thyroid cancer	0.000223	0.000408	CcSEcCtD
Paroxetine—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000221	0.000404	CcSEcCtD
Paroxetine—Epistaxis—Doxorubicin—thyroid cancer	0.000221	0.000403	CcSEcCtD
Paroxetine—Sinusitis—Doxorubicin—thyroid cancer	0.000219	0.000401	CcSEcCtD
Paroxetine—Visual impairment—Epirubicin—thyroid cancer	0.000219	0.0004	CcSEcCtD
Paroxetine—CHRM5—head—thyroid cancer	0.000219	0.0569	CbGeAlD
Paroxetine—Agranulocytosis—Doxorubicin—thyroid cancer	0.000218	0.000399	CcSEcCtD
Paroxetine—Erythema multiforme—Epirubicin—thyroid cancer	0.000215	0.000392	CcSEcCtD
Paroxetine—Bradycardia—Doxorubicin—thyroid cancer	0.000214	0.000391	CcSEcCtD
Paroxetine—Eye disorder—Epirubicin—thyroid cancer	0.000212	0.000388	CcSEcCtD
Paroxetine—Tinnitus—Epirubicin—thyroid cancer	0.000212	0.000387	CcSEcCtD
Paroxetine—Haemoglobin—Doxorubicin—thyroid cancer	0.000211	0.000386	CcSEcCtD
Paroxetine—Flushing—Epirubicin—thyroid cancer	0.000211	0.000385	CcSEcCtD
Paroxetine—Cardiac disorder—Epirubicin—thyroid cancer	0.000211	0.000385	CcSEcCtD
Paroxetine—Rhinitis—Doxorubicin—thyroid cancer	0.000211	0.000385	CcSEcCtD
Paroxetine—Hepatitis—Doxorubicin—thyroid cancer	0.00021	0.000384	CcSEcCtD
Paroxetine—Haemorrhage—Doxorubicin—thyroid cancer	0.00021	0.000384	CcSEcCtD
Paroxetine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000209	0.000382	CcSEcCtD
Paroxetine—Pharyngitis—Doxorubicin—thyroid cancer	0.000208	0.000381	CcSEcCtD
Paroxetine—TACR1—lymph node—thyroid cancer	0.000208	0.0542	CbGeAlD
Paroxetine—Oedema peripheral—Doxorubicin—thyroid cancer	0.000207	0.000378	CcSEcCtD
Paroxetine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000206	0.000377	CcSEcCtD
Paroxetine—Angiopathy—Epirubicin—thyroid cancer	0.000206	0.000376	CcSEcCtD
Paroxetine—Immune system disorder—Epirubicin—thyroid cancer	0.000205	0.000375	CcSEcCtD
Paroxetine—Mediastinal disorder—Epirubicin—thyroid cancer	0.000205	0.000374	CcSEcCtD
Paroxetine—Chills—Epirubicin—thyroid cancer	0.000204	0.000372	CcSEcCtD
Paroxetine—Arrhythmia—Epirubicin—thyroid cancer	0.000203	0.000371	CcSEcCtD
Paroxetine—Visual impairment—Doxorubicin—thyroid cancer	0.000202	0.00037	CcSEcCtD
Paroxetine—Alopecia—Epirubicin—thyroid cancer	0.000201	0.000367	CcSEcCtD
Paroxetine—Mental disorder—Epirubicin—thyroid cancer	0.000199	0.000364	CcSEcCtD
Paroxetine—Erythema multiforme—Doxorubicin—thyroid cancer	0.000199	0.000363	CcSEcCtD
Paroxetine—Erythema—Epirubicin—thyroid cancer	0.000198	0.000361	CcSEcCtD
Paroxetine—Malnutrition—Epirubicin—thyroid cancer	0.000198	0.000361	CcSEcCtD
Paroxetine—Eye disorder—Doxorubicin—thyroid cancer	0.000196	0.000359	CcSEcCtD
Paroxetine—Tinnitus—Doxorubicin—thyroid cancer	0.000196	0.000358	CcSEcCtD
Paroxetine—Cardiac disorder—Doxorubicin—thyroid cancer	0.000195	0.000356	CcSEcCtD
Paroxetine—Flushing—Doxorubicin—thyroid cancer	0.000195	0.000356	CcSEcCtD
Paroxetine—Flatulence—Epirubicin—thyroid cancer	0.000195	0.000356	CcSEcCtD
Paroxetine—CHRM1—trachea—thyroid cancer	0.000195	0.0506	CbGeAlD
Paroxetine—Tension—Epirubicin—thyroid cancer	0.000194	0.000354	CcSEcCtD
Paroxetine—Dysgeusia—Epirubicin—thyroid cancer	0.000193	0.000354	CcSEcCtD
Paroxetine—Nervousness—Epirubicin—thyroid cancer	0.000192	0.000351	CcSEcCtD
Paroxetine—Back pain—Epirubicin—thyroid cancer	0.000191	0.000349	CcSEcCtD
Paroxetine—Angiopathy—Doxorubicin—thyroid cancer	0.000191	0.000348	CcSEcCtD
Paroxetine—Muscle spasms—Epirubicin—thyroid cancer	0.00019	0.000347	CcSEcCtD
Paroxetine—Immune system disorder—Doxorubicin—thyroid cancer	0.00019	0.000347	CcSEcCtD
Paroxetine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000189	0.000346	CcSEcCtD
Paroxetine—Chills—Doxorubicin—thyroid cancer	0.000188	0.000345	CcSEcCtD
Paroxetine—Arrhythmia—Doxorubicin—thyroid cancer	0.000188	0.000343	CcSEcCtD
Paroxetine—Vision blurred—Epirubicin—thyroid cancer	0.000186	0.00034	CcSEcCtD
Paroxetine—Alopecia—Doxorubicin—thyroid cancer	0.000186	0.000339	CcSEcCtD
Paroxetine—Mental disorder—Doxorubicin—thyroid cancer	0.000184	0.000336	CcSEcCtD
Paroxetine—Ill-defined disorder—Epirubicin—thyroid cancer	0.000183	0.000335	CcSEcCtD
Paroxetine—Erythema—Doxorubicin—thyroid cancer	0.000183	0.000334	CcSEcCtD
Paroxetine—Malnutrition—Doxorubicin—thyroid cancer	0.000183	0.000334	CcSEcCtD
Paroxetine—Anaemia—Epirubicin—thyroid cancer	0.000183	0.000334	CcSEcCtD
Paroxetine—Agitation—Epirubicin—thyroid cancer	0.000182	0.000332	CcSEcCtD
Paroxetine—Flatulence—Doxorubicin—thyroid cancer	0.00018	0.000329	CcSEcCtD
Paroxetine—Tension—Doxorubicin—thyroid cancer	0.000179	0.000328	CcSEcCtD
Paroxetine—Dysgeusia—Doxorubicin—thyroid cancer	0.000179	0.000327	CcSEcCtD
Paroxetine—Malaise—Epirubicin—thyroid cancer	0.000178	0.000326	CcSEcCtD
Paroxetine—Nervousness—Doxorubicin—thyroid cancer	0.000178	0.000325	CcSEcCtD
Paroxetine—Vertigo—Epirubicin—thyroid cancer	0.000178	0.000325	CcSEcCtD
Paroxetine—Syncope—Epirubicin—thyroid cancer	0.000177	0.000324	CcSEcCtD
Paroxetine—Leukopenia—Epirubicin—thyroid cancer	0.000177	0.000323	CcSEcCtD
Paroxetine—Back pain—Doxorubicin—thyroid cancer	0.000177	0.000323	CcSEcCtD
Paroxetine—Muscle spasms—Doxorubicin—thyroid cancer	0.000176	0.000321	CcSEcCtD
Paroxetine—Palpitations—Epirubicin—thyroid cancer	0.000175	0.000319	CcSEcCtD
Paroxetine—Loss of consciousness—Epirubicin—thyroid cancer	0.000174	0.000317	CcSEcCtD
Paroxetine—Cough—Epirubicin—thyroid cancer	0.000172	0.000315	CcSEcCtD
Paroxetine—Vision blurred—Doxorubicin—thyroid cancer	0.000172	0.000315	CcSEcCtD
Paroxetine—HTR2A—neck—thyroid cancer	0.000172	0.0447	CbGeAlD
Paroxetine—Convulsion—Epirubicin—thyroid cancer	0.000171	0.000313	CcSEcCtD
Paroxetine—Hypertension—Epirubicin—thyroid cancer	0.000171	0.000312	CcSEcCtD
Paroxetine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00017	0.00031	CcSEcCtD
Paroxetine—Anaemia—Doxorubicin—thyroid cancer	0.000169	0.000309	CcSEcCtD
Paroxetine—Myalgia—Epirubicin—thyroid cancer	0.000168	0.000308	CcSEcCtD
Paroxetine—Chest pain—Epirubicin—thyroid cancer	0.000168	0.000308	CcSEcCtD
Paroxetine—Arthralgia—Epirubicin—thyroid cancer	0.000168	0.000308	CcSEcCtD
Paroxetine—Agitation—Doxorubicin—thyroid cancer	0.000168	0.000307	CcSEcCtD
Paroxetine—Anxiety—Epirubicin—thyroid cancer	0.000168	0.000306	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000167	0.000305	CcSEcCtD
Paroxetine—Discomfort—Epirubicin—thyroid cancer	0.000166	0.000304	CcSEcCtD
Paroxetine—Malaise—Doxorubicin—thyroid cancer	0.000165	0.000301	CcSEcCtD
Paroxetine—Dry mouth—Epirubicin—thyroid cancer	0.000165	0.000301	CcSEcCtD
Paroxetine—Vertigo—Doxorubicin—thyroid cancer	0.000164	0.0003	CcSEcCtD
Paroxetine—Syncope—Doxorubicin—thyroid cancer	0.000164	0.0003	CcSEcCtD
Paroxetine—Leukopenia—Doxorubicin—thyroid cancer	0.000164	0.000299	CcSEcCtD
Paroxetine—Confusional state—Epirubicin—thyroid cancer	0.000163	0.000297	CcSEcCtD
Paroxetine—Palpitations—Doxorubicin—thyroid cancer	0.000162	0.000295	CcSEcCtD
Paroxetine—Anaphylactic shock—Epirubicin—thyroid cancer	0.000161	0.000295	CcSEcCtD
Paroxetine—Oedema—Epirubicin—thyroid cancer	0.000161	0.000295	CcSEcCtD
Paroxetine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000161	0.000294	CcSEcCtD
Paroxetine—Infection—Epirubicin—thyroid cancer	0.00016	0.000293	CcSEcCtD
Paroxetine—Cough—Doxorubicin—thyroid cancer	0.00016	0.000292	CcSEcCtD
Paroxetine—Shock—Epirubicin—thyroid cancer	0.000159	0.00029	CcSEcCtD
Paroxetine—Convulsion—Doxorubicin—thyroid cancer	0.000158	0.00029	CcSEcCtD
Paroxetine—Nervous system disorder—Epirubicin—thyroid cancer	0.000158	0.000289	CcSEcCtD
Paroxetine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000158	0.000289	CcSEcCtD
Paroxetine—Hypertension—Doxorubicin—thyroid cancer	0.000158	0.000289	CcSEcCtD
Paroxetine—Tachycardia—Epirubicin—thyroid cancer	0.000157	0.000288	CcSEcCtD
Paroxetine—Skin disorder—Epirubicin—thyroid cancer	0.000157	0.000286	CcSEcCtD
Paroxetine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000156	0.000285	CcSEcCtD
Paroxetine—Chest pain—Doxorubicin—thyroid cancer	0.000156	0.000285	CcSEcCtD
Paroxetine—Arthralgia—Doxorubicin—thyroid cancer	0.000156	0.000285	CcSEcCtD
Paroxetine—Myalgia—Doxorubicin—thyroid cancer	0.000156	0.000285	CcSEcCtD
Paroxetine—Anxiety—Doxorubicin—thyroid cancer	0.000155	0.000284	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000155	0.000283	CcSEcCtD
Paroxetine—Discomfort—Doxorubicin—thyroid cancer	0.000154	0.000281	CcSEcCtD
Paroxetine—Dry mouth—Doxorubicin—thyroid cancer	0.000152	0.000278	CcSEcCtD
Paroxetine—Hypotension—Epirubicin—thyroid cancer	0.000151	0.000275	CcSEcCtD
Paroxetine—Confusional state—Doxorubicin—thyroid cancer	0.00015	0.000275	CcSEcCtD
Paroxetine—CHRM2—head—thyroid cancer	0.00015	0.039	CbGeAlD
Paroxetine—SLC6A3—head—thyroid cancer	0.00015	0.0389	CbGeAlD
Paroxetine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000149	0.000273	CcSEcCtD
Paroxetine—Oedema—Doxorubicin—thyroid cancer	0.000149	0.000273	CcSEcCtD
Paroxetine—Infection—Doxorubicin—thyroid cancer	0.000148	0.000271	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000147	0.000269	CcSEcCtD
Paroxetine—Shock—Doxorubicin—thyroid cancer	0.000147	0.000268	CcSEcCtD
Paroxetine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000146	0.000268	CcSEcCtD
Paroxetine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000146	0.000267	CcSEcCtD
Paroxetine—Insomnia—Epirubicin—thyroid cancer	0.000146	0.000267	CcSEcCtD
Paroxetine—Tachycardia—Doxorubicin—thyroid cancer	0.000146	0.000266	CcSEcCtD
Paroxetine—Skin disorder—Doxorubicin—thyroid cancer	0.000145	0.000265	CcSEcCtD
Paroxetine—Paraesthesia—Epirubicin—thyroid cancer	0.000145	0.000265	CcSEcCtD
Paroxetine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000144	0.000264	CcSEcCtD
Paroxetine—Dyspnoea—Epirubicin—thyroid cancer	0.000144	0.000263	CcSEcCtD
Paroxetine—Somnolence—Epirubicin—thyroid cancer	0.000143	0.000262	CcSEcCtD
Paroxetine—Dyspepsia—Epirubicin—thyroid cancer	0.000142	0.00026	CcSEcCtD
Paroxetine—Decreased appetite—Epirubicin—thyroid cancer	0.00014	0.000256	CcSEcCtD
Paroxetine—Hypotension—Doxorubicin—thyroid cancer	0.000139	0.000255	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000139	0.000255	CcSEcCtD
Paroxetine—Fatigue—Epirubicin—thyroid cancer	0.000139	0.000254	CcSEcCtD
Paroxetine—Constipation—Epirubicin—thyroid cancer	0.000138	0.000252	CcSEcCtD
Paroxetine—Pain—Epirubicin—thyroid cancer	0.000138	0.000252	CcSEcCtD
Paroxetine—CHRM3—thyroid gland—thyroid cancer	0.000138	0.0358	CbGeAlD
Paroxetine—SLC6A4—head—thyroid cancer	0.000137	0.0357	CbGeAlD
Paroxetine—CHRM1—head—thyroid cancer	0.000137	0.0355	CbGeAlD
Paroxetine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000136	0.000249	CcSEcCtD
Paroxetine—Insomnia—Doxorubicin—thyroid cancer	0.000135	0.000247	CcSEcCtD
Paroxetine—Paraesthesia—Doxorubicin—thyroid cancer	0.000134	0.000245	CcSEcCtD
Paroxetine—Dyspnoea—Doxorubicin—thyroid cancer	0.000133	0.000243	CcSEcCtD
Paroxetine—Feeling abnormal—Epirubicin—thyroid cancer	0.000133	0.000243	CcSEcCtD
Paroxetine—Somnolence—Doxorubicin—thyroid cancer	0.000133	0.000242	CcSEcCtD
Paroxetine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000132	0.000241	CcSEcCtD
Paroxetine—Dyspepsia—Doxorubicin—thyroid cancer	0.000131	0.00024	CcSEcCtD
Paroxetine—Decreased appetite—Doxorubicin—thyroid cancer	0.00013	0.000237	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000129	0.000235	CcSEcCtD
Paroxetine—Fatigue—Doxorubicin—thyroid cancer	0.000129	0.000235	CcSEcCtD
Paroxetine—Urticaria—Epirubicin—thyroid cancer	0.000128	0.000234	CcSEcCtD
Paroxetine—Pain—Doxorubicin—thyroid cancer	0.000128	0.000233	CcSEcCtD
Paroxetine—Constipation—Doxorubicin—thyroid cancer	0.000128	0.000233	CcSEcCtD
Paroxetine—Body temperature increased—Epirubicin—thyroid cancer	0.000127	0.000233	CcSEcCtD
Paroxetine—Abdominal pain—Epirubicin—thyroid cancer	0.000127	0.000233	CcSEcCtD
Paroxetine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000123	0.000225	CcSEcCtD
Paroxetine—CHRM3—head—thyroid cancer	0.000122	0.0318	CbGeAlD
Paroxetine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000122	0.000223	CcSEcCtD
Paroxetine—SLC6A2—head—thyroid cancer	0.000121	0.0314	CbGeAlD
Paroxetine—Hypersensitivity—Epirubicin—thyroid cancer	0.000119	0.000217	CcSEcCtD
Paroxetine—Urticaria—Doxorubicin—thyroid cancer	0.000119	0.000217	CcSEcCtD
Paroxetine—Body temperature increased—Doxorubicin—thyroid cancer	0.000118	0.000216	CcSEcCtD
Paroxetine—Abdominal pain—Doxorubicin—thyroid cancer	0.000118	0.000216	CcSEcCtD
Paroxetine—Asthenia—Epirubicin—thyroid cancer	0.000116	0.000212	CcSEcCtD
Paroxetine—Pruritus—Epirubicin—thyroid cancer	0.000114	0.000209	CcSEcCtD
Paroxetine—Diarrhoea—Epirubicin—thyroid cancer	0.00011	0.000202	CcSEcCtD
Paroxetine—Hypersensitivity—Doxorubicin—thyroid cancer	0.00011	0.000201	CcSEcCtD
Paroxetine—Asthenia—Doxorubicin—thyroid cancer	0.000107	0.000196	CcSEcCtD
Paroxetine—Dizziness—Epirubicin—thyroid cancer	0.000107	0.000195	CcSEcCtD
Paroxetine—Pruritus—Doxorubicin—thyroid cancer	0.000106	0.000193	CcSEcCtD
Paroxetine—HTR2A—trachea—thyroid cancer	0.000103	0.0269	CbGeAlD
Paroxetine—Vomiting—Epirubicin—thyroid cancer	0.000103	0.000187	CcSEcCtD
Paroxetine—Diarrhoea—Doxorubicin—thyroid cancer	0.000102	0.000187	CcSEcCtD
Paroxetine—Rash—Epirubicin—thyroid cancer	0.000102	0.000186	CcSEcCtD
Paroxetine—Dermatitis—Epirubicin—thyroid cancer	0.000102	0.000186	CcSEcCtD
Paroxetine—Headache—Epirubicin—thyroid cancer	0.000101	0.000185	CcSEcCtD
Paroxetine—Dizziness—Doxorubicin—thyroid cancer	9.87e-05	0.00018	CcSEcCtD
Paroxetine—Nausea—Epirubicin—thyroid cancer	9.58e-05	0.000175	CcSEcCtD
Paroxetine—Vomiting—Doxorubicin—thyroid cancer	9.49e-05	0.000173	CcSEcCtD
Paroxetine—Rash—Doxorubicin—thyroid cancer	9.41e-05	0.000172	CcSEcCtD
Paroxetine—Dermatitis—Doxorubicin—thyroid cancer	9.4e-05	0.000172	CcSEcCtD
Paroxetine—Headache—Doxorubicin—thyroid cancer	9.35e-05	0.000171	CcSEcCtD
Paroxetine—CYP2B6—head—thyroid cancer	8.9e-05	0.0231	CbGeAlD
Paroxetine—Nausea—Doxorubicin—thyroid cancer	8.86e-05	0.000162	CcSEcCtD
Paroxetine—SLC6A2—lymph node—thyroid cancer	8.45e-05	0.022	CbGeAlD
Paroxetine—HTR2A—head—thyroid cancer	7.26e-05	0.0189	CbGeAlD
Paroxetine—ABCB1—trachea—thyroid cancer	6.78e-05	0.0176	CbGeAlD
Paroxetine—CYP2D6—head—thyroid cancer	6.61e-05	0.0172	CbGeAlD
Paroxetine—CHRM2—GPCR downstream signaling—SST—thyroid cancer	5.79e-05	0.00075	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	5.78e-05	0.000749	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	5.75e-05	0.000745	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PTCH1—thyroid cancer	5.74e-05	0.000745	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TSHR—thyroid cancer	5.74e-05	0.000744	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	5.73e-05	0.000743	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CALCA—thyroid cancer	5.67e-05	0.000735	CbGpPWpGaD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—HRAS—thyroid cancer	5.67e-05	0.000735	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PRKAR1A—thyroid cancer	5.65e-05	0.000732	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CALCA—thyroid cancer	5.64e-05	0.000731	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MEN1—thyroid cancer	5.64e-05	0.000731	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CALCA—thyroid cancer	5.62e-05	0.000729	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CALCA—thyroid cancer	5.57e-05	0.000722	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TCF7L1—thyroid cancer	5.55e-05	0.00072	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TCF7L1—thyroid cancer	5.52e-05	0.000716	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TCF7L1—thyroid cancer	5.51e-05	0.000714	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TCF7L1—thyroid cancer	5.45e-05	0.000707	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MEN1—thyroid cancer	5.4e-05	0.0007	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—NRAS—thyroid cancer	5.37e-05	0.000696	CbGpPWpGaD
Paroxetine—ABCB1—thyroid gland—thyroid cancer	5.36e-05	0.0139	CbGeAlD
Paroxetine—HTR2A—Signaling by GPCR—SST—thyroid cancer	5.35e-05	0.000694	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—HPGD—thyroid cancer	5.32e-05	0.00069	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—SST—thyroid cancer	5.32e-05	0.00069	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—SST—thyroid cancer	5.31e-05	0.000688	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—SST—thyroid cancer	5.25e-05	0.000681	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CALCA—thyroid cancer	5.15e-05	0.000668	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	5.14e-05	0.000666	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CALCA—thyroid cancer	5.12e-05	0.000664	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CALCA—thyroid cancer	5.11e-05	0.000662	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PTCH1—thyroid cancer	5.1e-05	0.000661	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CALCA—thyroid cancer	5.06e-05	0.000656	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—BRAF—thyroid cancer	5.05e-05	0.000655	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—HPGD—thyroid cancer	5.02e-05	0.00065	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	4.97e-05	0.000645	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—HPGD—thyroid cancer	4.97e-05	0.000645	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.96e-05	0.000643	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	4.95e-05	0.000641	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	4.93e-05	0.000639	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.89e-05	0.000634	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTCH1—thyroid cancer	4.88e-05	0.000633	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—TPR—thyroid cancer	4.82e-05	0.000625	CbGpPWpGaD
Paroxetine—ABCB1—head—thyroid cancer	4.76e-05	0.0124	CbGeAlD
Paroxetine—CHRM3—Metabolism—PRKAR1A—thyroid cancer	4.74e-05	0.000615	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SST—thyroid cancer	4.66e-05	0.000604	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CDK1—thyroid cancer	4.66e-05	0.000604	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	4.64e-05	0.000602	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—TP53—thyroid cancer	4.64e-05	0.000602	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CDK1—thyroid cancer	4.64e-05	0.000601	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—KRAS—thyroid cancer	4.62e-05	0.000599	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CDK1—thyroid cancer	4.62e-05	0.000599	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CDK1—thyroid cancer	4.58e-05	0.000593	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CALCA—thyroid cancer	4.49e-05	0.000582	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	4.48e-05	0.000581	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SST—thyroid cancer	4.47e-05	0.000579	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—HRAS—thyroid cancer	4.34e-05	0.000563	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CALCA—thyroid cancer	4.3e-05	0.000557	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	4.23e-05	0.000548	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	4.21e-05	0.000545	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	4.19e-05	0.000543	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—TPR—thyroid cancer	4.15e-05	0.000537	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.11e-05	0.000532	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PRKAR1A—thyroid cancer	4.08e-05	0.000529	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TSHR—thyroid cancer	4.06e-05	0.000527	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CDK1—thyroid cancer	4.06e-05	0.000527	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TSHR—thyroid cancer	4.04e-05	0.000524	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.03e-05	0.000523	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TSHR—thyroid cancer	4.03e-05	0.000522	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PRKAR1A—thyroid cancer	4e-05	0.000518	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TSHR—thyroid cancer	3.99e-05	0.000517	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PRKAR1A—thyroid cancer	3.98e-05	0.000516	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PRKAR1A—thyroid cancer	3.96e-05	0.000514	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—HRAS—thyroid cancer	3.93e-05	0.00051	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PRKAR1A—thyroid cancer	3.93e-05	0.000509	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CDK1—thyroid cancer	3.89e-05	0.000504	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—AKT1—thyroid cancer	3.82e-05	0.000495	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MEN1—thyroid cancer	3.82e-05	0.000495	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MEN1—thyroid cancer	3.8e-05	0.000493	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MEN1—thyroid cancer	3.79e-05	0.000491	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MEN1—thyroid cancer	3.75e-05	0.000486	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CCND1—thyroid cancer	3.69e-05	0.000478	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—SLC5A5—thyroid cancer	3.61e-05	0.000468	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—PTEN—thyroid cancer	3.56e-05	0.000461	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TPR—thyroid cancer	3.51e-05	0.000455	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—AKT1—thyroid cancer	3.47e-05	0.00045	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTCH1—thyroid cancer	3.46e-05	0.000448	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	3.45e-05	0.000448	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	3.44e-05	0.000446	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTCH1—thyroid cancer	3.44e-05	0.000446	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTCH1—thyroid cancer	3.43e-05	0.000444	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTCH1—thyroid cancer	3.39e-05	0.00044	CbGpPWpGaD
Paroxetine—ABCB1—lymph node—thyroid cancer	3.33e-05	0.00866	CbGeAlD
Paroxetine—CHRM4—Signaling Pathways—NRG1—thyroid cancer	3.26e-05	0.000423	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—NRAS—thyroid cancer	3.17e-05	0.000411	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SST—thyroid cancer	3.16e-05	0.00041	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SST—thyroid cancer	3.14e-05	0.000408	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SST—thyroid cancer	3.13e-05	0.000406	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.13e-05	0.000406	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NRG1—thyroid cancer	3.12e-05	0.000405	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—SLC5A5—thyroid cancer	3.1e-05	0.000402	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SST—thyroid cancer	3.1e-05	0.000402	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TPR—thyroid cancer	3.06e-05	0.000396	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	3.06e-05	0.000396	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CALCA—thyroid cancer	3.04e-05	0.000394	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—RXRA—thyroid cancer	3.03e-05	0.000393	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CALCA—thyroid cancer	3.03e-05	0.000392	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CALCA—thyroid cancer	3.02e-05	0.000391	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PRKAR1A—thyroid cancer	3.01e-05	0.00039	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CALCA—thyroid cancer	2.99e-05	0.000387	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TERT—thyroid cancer	2.93e-05	0.00038	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TPR—thyroid cancer	2.88e-05	0.000374	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TPR—thyroid cancer	2.86e-05	0.00037	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	2.84e-05	0.000368	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	2.81e-05	0.000364	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TERT—thyroid cancer	2.8e-05	0.000363	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HIF1A—thyroid cancer	2.8e-05	0.000363	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDK1—thyroid cancer	2.75e-05	0.000357	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDK1—thyroid cancer	2.74e-05	0.000355	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—KRAS—thyroid cancer	2.73e-05	0.000354	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDK1—thyroid cancer	2.73e-05	0.000354	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDK1—thyroid cancer	2.7e-05	0.000351	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HIF1A—thyroid cancer	2.68e-05	0.000348	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—SLC5A5—thyroid cancer	2.63e-05	0.000341	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—RXRA—thyroid cancer	2.61e-05	0.000338	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.58e-05	0.000335	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.55e-05	0.00033	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—NRAS—thyroid cancer	2.47e-05	0.00032	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.46e-05	0.000319	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TP53—thyroid cancer	2.43e-05	0.000315	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—NRAS—thyroid cancer	2.36e-05	0.000306	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—HRAS—thyroid cancer	2.32e-05	0.000301	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—BRAF—thyroid cancer	2.32e-05	0.000301	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SLC5A5—thyroid cancer	2.29e-05	0.000297	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—BRAF—thyroid cancer	2.22e-05	0.000288	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NRG1—thyroid cancer	2.21e-05	0.000287	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—RXRA—thyroid cancer	2.21e-05	0.000286	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NRG1—thyroid cancer	2.2e-05	0.000285	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NRG1—thyroid cancer	2.19e-05	0.000284	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NRG1—thyroid cancer	2.17e-05	0.000281	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SLC5A5—thyroid cancer	2.16e-05	0.00028	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.15e-05	0.000278	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SLC5A5—thyroid cancer	2.14e-05	0.000277	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—KRAS—thyroid cancer	2.12e-05	0.000275	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—AKT1—thyroid cancer	2.05e-05	0.000266	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—KRAS—thyroid cancer	2.03e-05	0.000264	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2e-05	0.00026	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TERT—thyroid cancer	1.99e-05	0.000257	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TERT—thyroid cancer	1.97e-05	0.000256	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TERT—thyroid cancer	1.97e-05	0.000255	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TERT—thyroid cancer	1.95e-05	0.000253	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—RXRA—thyroid cancer	1.92e-05	0.000249	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PPARG—thyroid cancer	1.91e-05	0.000248	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HIF1A—thyroid cancer	1.9e-05	0.000246	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HIF1A—thyroid cancer	1.89e-05	0.000245	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HIF1A—thyroid cancer	1.88e-05	0.000244	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HIF1A—thyroid cancer	1.86e-05	0.000242	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—RXRA—thyroid cancer	1.81e-05	0.000235	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—HRAS—thyroid cancer	1.8e-05	0.000234	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—RXRA—thyroid cancer	1.8e-05	0.000233	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AKT1—thyroid cancer	1.75e-05	0.000227	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.75e-05	0.000227	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HRAS—thyroid cancer	1.73e-05	0.000224	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCND1—thyroid cancer	1.69e-05	0.000219	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AKT1—thyroid cancer	1.68e-05	0.000218	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	1.67e-05	0.000217	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—NRAS—thyroid cancer	1.66e-05	0.000216	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—NRAS—thyroid cancer	1.66e-05	0.000215	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PPARG—thyroid cancer	1.65e-05	0.000213	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—NRAS—thyroid cancer	1.64e-05	0.000213	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PTEN—thyroid cancer	1.63e-05	0.000212	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCND1—thyroid cancer	1.62e-05	0.00021	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—thyroid cancer	1.59e-05	0.000207	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—BRAF—thyroid cancer	1.57e-05	0.000204	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTEN—thyroid cancer	1.56e-05	0.000203	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—BRAF—thyroid cancer	1.56e-05	0.000203	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—BRAF—thyroid cancer	1.56e-05	0.000202	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—BRAF—thyroid cancer	1.54e-05	0.0002	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—thyroid cancer	1.53e-05	0.000198	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—thyroid cancer	1.51e-05	0.000195	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NRAS—thyroid cancer	1.46e-05	0.000189	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	1.44e-05	0.000187	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—KRAS—thyroid cancer	1.43e-05	0.000186	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—KRAS—thyroid cancer	1.43e-05	0.000185	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—KRAS—thyroid cancer	1.41e-05	0.000183	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NRAS—thyroid cancer	1.4e-05	0.000181	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARG—thyroid cancer	1.39e-05	0.000181	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTEN—thyroid cancer	1.31e-05	0.00017	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—thyroid cancer	1.3e-05	0.000168	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KRAS—thyroid cancer	1.25e-05	0.000163	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	1.22e-05	0.000159	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRAS—thyroid cancer	1.22e-05	0.000158	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARG—thyroid cancer	1.21e-05	0.000157	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRAS—thyroid cancer	1.21e-05	0.000157	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRAS—thyroid cancer	1.2e-05	0.000156	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KRAS—thyroid cancer	1.2e-05	0.000156	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	1.19e-05	0.000154	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—thyroid cancer	1.18e-05	0.000153	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—thyroid cancer	1.18e-05	0.000153	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—thyroid cancer	1.17e-05	0.000151	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCND1—thyroid cancer	1.15e-05	0.000149	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARG—thyroid cancer	1.14e-05	0.000148	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCND1—thyroid cancer	1.14e-05	0.000148	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCND1—thyroid cancer	1.14e-05	0.000147	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARG—thyroid cancer	1.13e-05	0.000147	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTEN—thyroid cancer	1.13e-05	0.000146	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCND1—thyroid cancer	1.13e-05	0.000146	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—thyroid cancer	1.11e-05	0.000145	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTEN—thyroid cancer	1.11e-05	0.000144	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTEN—thyroid cancer	1.1e-05	0.000143	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTEN—thyroid cancer	1.1e-05	0.000142	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—thyroid cancer	1.1e-05	0.000142	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTEN—thyroid cancer	1.09e-05	0.000141	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	1.08e-05	0.00014	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—thyroid cancer	1.07e-05	0.000139	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—thyroid cancer	1.07e-05	0.000139	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—thyroid cancer	1.07e-05	0.000138	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRAS—thyroid cancer	1.07e-05	0.000138	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—thyroid cancer	1.06e-05	0.000137	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRAS—thyroid cancer	1.02e-05	0.000132	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NRAS—thyroid cancer	9.88e-06	0.000128	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NRAS—thyroid cancer	9.83e-06	0.000127	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NRAS—thyroid cancer	9.8e-06	0.000127	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NRAS—thyroid cancer	9.7e-06	0.000126	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTEN—thyroid cancer	9.56e-06	0.000124	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—thyroid cancer	9.55e-06	0.000124	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—thyroid cancer	9.41e-06	0.000122	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—thyroid cancer	9.02e-06	0.000117	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—thyroid cancer	9e-06	0.000117	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—thyroid cancer	8.92e-06	0.000116	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KRAS—thyroid cancer	8.5e-06	0.00011	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KRAS—thyroid cancer	8.46e-06	0.00011	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KRAS—thyroid cancer	8.43e-06	0.000109	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KRAS—thyroid cancer	8.35e-06	0.000108	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTEN—thyroid cancer	8.33e-06	0.000108	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTEN—thyroid cancer	7.85e-06	0.000102	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTEN—thyroid cancer	7.78e-06	0.000101	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—thyroid cancer	7.57e-06	9.81e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—thyroid cancer	7.56e-06	9.8e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—thyroid cancer	7.52e-06	9.74e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—thyroid cancer	7.49e-06	9.71e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—thyroid cancer	7.42e-06	9.62e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRAS—thyroid cancer	7.23e-06	9.37e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRAS—thyroid cancer	7.19e-06	9.32e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRAS—thyroid cancer	7.17e-06	9.29e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRAS—thyroid cancer	7.1e-06	9.2e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—thyroid cancer	6.51e-06	8.44e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—thyroid cancer	6.38e-06	8.27e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—thyroid cancer	6.35e-06	8.23e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—thyroid cancer	6.33e-06	8.2e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—thyroid cancer	6.27e-06	8.12e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—thyroid cancer	5.51e-06	7.14e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—thyroid cancer	4.8e-06	6.22e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—thyroid cancer	4.52e-06	5.87e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—thyroid cancer	4.49e-06	5.81e-05	CbGpPWpGaD
